Eubelius assisted the new investors MPM Capital, HBM Partners, 6 Dimensions Capital and Curative Ventures in the € 64 million Series B financing round of iTeos Therapeutics NV.
iTeos Therapeutics is a Belgian biotechnology company developing novel cancer immunotherapies.
The team members involved in the transaction were Lars Van Bever, Filip Jenné and Elias Van Marcke.
For more information, see the press release and De Tijd.